Financial hardship related to treatment costs is a common reality for many men with metastatic prostate cancer.
Investigators compared ADT plus abiraterone or docetaxel with ADT alone.
New data suggest that, from 1990 to 2019, the global incidence of early-onset cancer increased by nearly 80%, and the rate of early-onset cancer deaths increased by nearly 30%.
A PSA decrease of 30% or more occurred in 77.8% of patients after the third treatment cycle, investigators report.
Investigators believe their study is the first to demonstrate the adverse impact of LVI on overall survival in patients with surgically treated renal cell carcinoma.